Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|December 12, 2013

J&J Innovation Announces Opening of Offices

Johnson&Johnson will open a network of partnering offices across the UK.

Johnson & Johnson (J&J) Innovation, a division of J&J reported the formation of a network of partnering offices across UK life science clusters. The offices function as extensions of its London Innovation Center to work with academics and entrepreneurs throughout the UK to identify early-stage innovation and support the translation of research into new products for patients.

While the London Innovation Center continues to be the primary hub for interactions with the academic and entrepreneurial community in the greater London area, these new partnering offices are part of a broader strategy to interact
more directly with life science “hotspots” throughout the UK and Europe. Johnson & Johnson Innovation is establishing partnering offices in the following locations that will function as a base for interactions throughout the regions:

  • Babraham Research Campus for the wider Cambridge area

  • University of Oxford Old Road Campus for the wider Oxford area

  • The University of Manchester Innovation Center (UMIC) for the North and Midlands

  • Edinburgh BioQuarter for Scotland and Northern Irelan

  • Life Sciences Hub Wales in Cardiff for Wales and the South West.

Representatives from the J&J Innovation Center in London will establish a regular presence in each of the partnering offices that are expected to be fully operational in early 2014.

Johnson & Johnson Innovation focuses on accelerating early innovation and enhancing opportunities for collaboration and investment across Johnson & Johnson’s global healthcare businesses.

Source: Johnson & Johnson


Related to this article

The BioPharm Brief: Cosentyx Approved in Polymyalgia Rheumatica, a Phase 3 Survival Win for an AML Vaccine, and $173 Million for In Vivo Bone Marrow Editing
FDA approves Novartis’ Cosentyx as the first anti-IL-17 biologic for polymyalgia rheumatica, SELLAS Life Sciences’ WT1-targeted peptide vaccine galinpepimut-S meets its overall survival primary endpoint in the phase 3 REGAL trial in AML, and Marrow Therapeutics launches with $173 million to develop bone marrow-targeted genetic medicines.